|
1
|
Chaturvedi R, Heimburg J, Yan J, Koury S, Sajjad M, Abdel-Nabi HH, Rittenhouse-Olson K. Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen. Appl Radiat Isot 2007; 66:278-87. [PMID: 17890096 PMCID: PMC3192430 DOI: 10.1016/j.apradiso.2007.07.029] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2007] [Revised: 05/18/2007] [Accepted: 07/05/2007] [Indexed: 10/22/2022]
Abstract
Clinical immunolocalization has been attempted by others with an anti-Thomsen-Friedenreich antigen (TF-Ag) mAb that bound both alpha- and beta-linked TF-Ag. In this report, 124 I-labeled mAb JAA-F11 specific for alpha-linked TF-Ag showed higher tumor specificity in in vivo micro-positron emission tomography (micro-PET) of the mouse mammary adenocarcinoma line, 4T1, showing no preferential uptake by the kidney. Labeled product remained localized in the tumor for at least 20 days. Glycan array analysis showed structural specificity of the antibody.
Collapse
Affiliation(s)
- Richa Chaturvedi
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Jamie Heimburg
- Department of Microbiology and Immunology, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Jun Yan
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Stephen Koury
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Munawwar Sajjad
- Department of Nuclear Medicine, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Hani H Abdel-Nabi
- Department of Nuclear Medicine, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Kate Rittenhouse-Olson
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
- Department of Microbiology and Immunology, University at Buffalo, the State University of New York, Buffalo, New York 14214
- Corresponding author: Kate Rittenhouse-Olson, 26 Cary Hall, 3435 Main St, Buffalo NY 14214, 716-829-3630 x116, fax 716-829-3601,
| |
Collapse
|
|
2
|
Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 2007; 8:939-48. [PMID: 17132226 PMCID: PMC1716011 DOI: 10.1593/neo.06493] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Thomsen-Friedenreich antigen (TF-Ag) is expressed in many carcinomas, including those of the breast, colon, bladder, and prostate. TF-Ag is important in adhesion and metastasis and as a potential immunotherapy target. We hypothesized that passive transfer of JAA-F11, an anti-TF-Ag monoclonal antibody, may create a survival advantage for patients with TF-Ag-expressing tumors by cytotoxicity, blocking of tumor cell adhesion, and inhibition of metastasis. This was tested using in vitro models of tumor cell growth; cytotoxicity assays; in vitro, ex vivo, and in vivo models of cancer metastasis; and, finally, in vivo effects in mice with metastatic breast cancer. Unlike some anti-TF-Ag antibodies, JAA-F11 did not enhance breast carcinoma cell growth. JAA-F11 did not induce the killing of 4T1 tumor cells through complement-dependent cytotoxicity or apoptotic mechanisms. However, JAA-F11 blocked the stages of metastasis that involve the adhesion of human breast carcinoma cells to human endothelial cells (human umbilical vein endothelial cells and human bone marrow endothelial cells 60) in in vitro static adhesion models, in a perfused ex vivo model, and in murine lung vasculature in an in vivo metastatic deposit formation assay. JAA-F11 significantly extended the median survival time of animals bearing metastatic 4T1 breast tumors and caused a > 50% inhibition of lung metastasis.
Collapse
Affiliation(s)
- Jamie Heimburg
- Department of Microbiology and Immunology, The University at Buffalo, Buffalo, NY 14214, USA
| | - Jun Yan
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Susan Morey
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Olga V Glinskii
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
| | - Virginia H Huxley
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
| | - Linda Wild
- Department of Pathology and Anatomical Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Robert Klick
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Rene Roy
- Department of Chemistry, University of Quebec at Montreal, Montreal, Quebec, Canada H3C 3P8
| | - Vladislav V Glinsky
- Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, MO 65201, USA
| | - Kate Rittenhouse-Olson
- Department of Microbiology and Immunology, The University at Buffalo, Buffalo, NY 14214, USA
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| |
Collapse
|